Markets & Regulations

Failure to launch? Mixed views on US biosimilar market

17-Jan-2020 By Ben Hargreaves

Differing reports on the impact of biosimilars in the US paint an unclear picture of what to expect in 2020.

Lilly acquires Dermira for $1.1bn, expands dermatology portfolio

15-Jan-2020 By Vassia Barba

Eli Lilly set to acquire dermatological drugs developer, Dermira, in an $1.1bn all-cash deal, adding commercial and late-stage drugs to its portfolio.

Astellas continues to make deals, partnering with Adaptimmune

15-Jan-2020 By Ben Hargreaves

The newly established deal includes the co-development of up to three T-cell therapies, by utilizing the latter’s stem-cell derived allogeneic T-cell platform.

Surging local demand drives 24% growth of Korean contract service sector

15-Jan-2020 By Nick Taylor

South Korean contract service market grows 24% as local biopharma companies step up spending.

Biocon biosimilar business valued at $3bn in funding round

14-Jan-2020 By Nick Taylor

Biocon Biologics receives True North investment that values biosimilar business at around $3bn.

FDA places Innate cancer trial on partial clinical hold over CMO issue

14-Jan-2020 By Nick Taylor

The US FDA puts Innate Pharma trial on partial clinical hold after learning of CMO problems.

Bristol-Myers offloads manufacturing plant to Catalent

13-Jan-2020 By Nick Taylor

Catalent buys Italian manufacturing and packaging plant from Bristol-Myers Squibb, adding oral solid, biologics and sterile product capacity.

Astellas acquires Xyphos and its CAR-T technology for $665m

09-Jan-2020 By Ben Hargreaves

Astellas continues its acquisition spree in the advanced therapeutics space through a deal for Xyphos and its next-generation take on CAR-T therapies.

China approves first vaccine since adoption of tougher standards

09-Jan-2020 By Nick Taylor

Sinovac becomes first company to win approval for a vaccine in China since the adoption of tougher standards.

Merck to initiate Ebola vaccine manufacture after FDA nod

08-Jan-2020 By Vassia Barba

Shortly after EMA’s approval, the US FDA follows with a positive nod for Ervebo, the first vaccine to receive approval for the prevention of Ebola virus disease.

Charles River closes $380m HemaCare cell therapy takeover

07-Jan-2020 By Nick Taylor

Charles River Laboratories closes $380m takeover of cell therapy specialist HemaCare to expand in fast-growing sector.

BeiGene receives nod for PD-1 treatment, Boehringer begins manufacture

07-Jan-2020 By Ben Hargreaves

BeiGene’s immunotherapy becomes its first treatment to receive approval in China and Boehringer announces that it has begun manufacture of the product.

Kamada signs manufacturing deal to fill capacity vacated by Takeda

07-Jan-2020 By Nick Taylor

Kamada signs contract manufacturing deal ahead of anticipated loss of Takeda business.

Filling UK bioprocessing roles a ‘substantial concern’

06-Jan-2020 By Ben Hargreaves

With the number of roles in manufacturing projected to rise by 196% over the next five years, industry fears a lack of expertise to fill vacuum, according to survey.